Las Vegas Doctor Loses DEA License Over Suspended State Permit
Published Date: 4/16/2025
Notice
Summary
Dr. Ajumobi Agu from Las Vegas lost his DEA license because he kept giving out controlled medicines after his state licenses were suspended. Since he didn’t ask for a hearing, the DEA decided to revoke his registration to keep the public safe. This means he can’t legally handle controlled substances anymore, effective immediately, protecting patients and the community.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
DEA Registration Revoked for Dr. Agu
The DEA revoked Ajumobi Agu, M.D.'s Certificate of Registration No. FA4195459 and denied any pending applications to renew, modify, or add a registration in Nevada. The revocation takes effect May 16, 2025, so Dr. Agu may no longer legally handle controlled substances under that DEA registration.
Public Safety Protected by Revocation
The DEA revoked Dr. Agu's registration to protect patients and the public after finding he issued about 22 controlled-substance prescriptions to 14 patients between June 30, 2023 and September 11, 2023 while his Nevada licenses were suspended. The Order is effective May 16, 2025, and aims to prevent further dispensing of controlled medicines by this registrant in Nevada.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17594, Atlantic Treatment Center, LLC; Decision and Order
2026-17589, Leila Kump, M.D.; Decision and Order
2026-17592, Thomas Earley, D.D.S.; Decision and Order
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
Previous / Next Documents
Previous: 2025-06451, Lattice-Boom Crawler Cranes (LBCCs) From Japan; Institution of Antidumping Duty Investigation and Scheduling of Preliminary Phase Investigation
The U.S. is launching an investigation to see if cheap lattice-boom crawler cranes from Japan are hurting American businesses. If they find unfair pricing, extra taxes might be added to these imports. The investigation’s first big decision is due by May 27, 2025, so things are moving fast!
Next: 2025-06453, Victor Augusto Silva, M.D.; Order
Dr. Victor Augusto Silva from Tampa had his DEA registration suspended and then revoked because he let someone else illegally use his license to prescribe drugs. Since he didn’t respond in time to defend himself, the government decided he’s a risk to public safety and took away his registration for good. This means he can’t legally prescribe controlled substances anymore, effective immediately.